These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 2961830)

  • 1. [Clinical usefulness of phosphofructokinase(PFK)-inhibition test as a tumor marker in the patients with solid tumor].
    Ogiwara H; Nara K; Takami H; Abe O; Nakamura K
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):966-76. PubMed ID: 2961830
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of two similar differential tumor markers based on phosphofructokinase activity arising from the influence of cancer patient serum.
    Nakamura K; Nakajima Y; Nakamura Y
    Cancer Detect Prev; 1988; 13(3-4):239-50. PubMed ID: 2977298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease of serum buffering capacity associated with malignant neoplasms.
    Nakamura K; Nakajima Y; Nakamura Y; Ogiwara H; Koide A
    Cancer Detect Prev; 1988; 13(3-4):175-87. PubMed ID: 2977297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of solid tumors by the PFK inhibition test].
    Takami H; Hagiwara H; Nakamura K; Abe O
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):389-90. PubMed ID: 2936308
    [No Abstract]   [Full Text] [Related]  

  • 5. A new cancer marker: a possible cancer screening method based on the suppression of phosphofructokinase by sera from cancer patients.
    Nakamura K; Kituta T; Takahashi T; Nakamura Y; Nakajima Y
    Cancer Detect Prev; 1985; 8(1-2):207-18. PubMed ID: 2933146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PFK inhibition test for cancer detection: clinical applications and mechanisms of PFK inhibition.
    Nakamura K; Kituta T; Nakamura Y; Nakajima Y; Kobayashi K; Uchida T
    Cancer Detect Prev; 1987; 10(1-2):37-55. PubMed ID: 2952272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumor markers in skeletal metastasis.
    Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
    Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of the tumor markers in the diagnosis of idiopathic deep venous thrombosis associated cancer].
    Enguídanos MJ; Todolí JA; Saro E; Salvador G; Villar J; Gómez-Biedma S; Micó L; Calabuig JR
    An Med Interna; 2002 Nov; 19(11):561-6. PubMed ID: 12522891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of gastrointestinal antigens in the monitoring of patients with malignant head neoplasms].
    Adamiak G; Jurkiewicz D; Ligeziński A; Hermanowski M; Konieczna M
    Pol Merkur Lekarski; 1998 Aug; 5(26):69-71. PubMed ID: 10101458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suppression of phosphofructokinase (PFK) by sera from cancer patients, and mechanism of the antagonistic effect of PSK].
    Nakamura K; Nakajima Y; Nomoto K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):970-6. PubMed ID: 2938549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis.
    Illert B; Fein M; Otto C; Cording F; Stehle D; Thiede A; Timmermann W
    Scand J Gastroenterol; 2005 Jul; 40(7):843-9. PubMed ID: 16109661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of serum markers for the early detection of colorectal cancer.
    Wild N; Andres H; Rollinger W; Krause F; Dilba P; Tacke M; Karl J
    Clin Cancer Res; 2010 Dec; 16(24):6111-21. PubMed ID: 20798228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy.
    Vora S; Halper JP; Knowles DM
    Cancer Res; 1985 Jul; 45(7):2993-3001. PubMed ID: 3159473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical usefulness of cytokeratin CYFRA 21.1 as a new tumor marker in the diagnosis of epidermoid carcinoma of the lung. Preliminary study].
    Cortés J; Genollá J; Casquero F; Fombellida JC
    Med Clin (Barc); 1993 Mar; 100(10):394. PubMed ID: 7682640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.